


Company Overview

Name	SymBio Pharmaceuticals Limited
Address	Toranomon 30 Mori Bldg., 3-2-2 Toranomon, Minato-ku, Tokyo 105-0001, Japan Tel: 03-5472-1125 Fax: 03-5472-3054
URL	https://www.symbiopharma.com
Established	March 25, 2005
Capital stock	JPY 17,548,459,551 (at the end of December 2022)
Board of Directors	Fuminori Yoshida Representative Director Shigetoshi Matsumoto <Outside> Bruce David Cheson <Outside> Eiji Ebinuma <Outside> Kiyoshi Watanabe Full-Time Audit & Supervisory Committee Member <Outside> Kesao Endo Audit & Supervisory Committee Member <Outside> Yasuhiro Tamo Audit & Supervisory Committee Member <Outside>
Corporate Officers	Fuminori Yoshida Corporate Officer, President and Chief Executive Officer Takaaki Fukushima Executive Corporate Officer, Chief Financial Officer Koji Fukushima Corporate Officer, Deputy Chief Medical Officer Yoshiharu Torikai Corporate Officer Masahiko Okuno Corporate Officer Hiroyuki Horita Corporate Officer Stephane Berthier Corporate Officer
Subsidiary	SymBio Pharma USA, Inc. Durham, North Carolina, USA Stephane Berthier Chief Executive Officer and President



Tokyo Metro Hibiya Line: 1 min walk from Toranomon Hills station Exit A1, A2
Tokyo Metro Hibiya Line: 6-min walk from Kamiyacho station Exit 4a
Tokyo Metro Ginza Line: 5-min. walk from Toranomon station Exit 2

History

As of September 11, 2023

Mar. 2005	SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, Tokyo
Jul. 2005	Head office relocates to Shimbashi, Minato-ku, Tokyo
Dec. 2005	License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan
Mar. 2006	Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government
Mar. 2007	License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore
Aug. 2008	License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan
Mar. 2009	SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK)
May. 2009	License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore
Oct. 2010	SymBio Pharmaceuticals announces NDA Approval of TREAKISYM® (bendamustine) in Japan
Dec. 2010	SymBio Pharmaceuticals launches TREAKISYM® in Japan
Jul. 2011	Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101 (rigosertib, a Phase III stage multi-kinase inhibitor for Myelodysplastic Syndromes)
Oct. 2011	Listed on Osaka Securities Exchange JASDAQ Growth Market
Nov. 2014	Head Office relocates to Toranomon, Minato-ku, Tokyo
May. 2016	SymBio Pharma USA, Inc. established at Menlo Park, California, USA
Aug. 2016	SymBio Pharmaceuticals announces the NDA approval of TREAKISYM® (bendamustine) for the additional indication of chronic lymphocytic leukemia in Japan
Dec. 2016	SymBio Pharmaceuticals announces the NDA approval of TREAKISYM® (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan
Sep. 2017	Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan * RTD: Ready-to-dilute, RI: Rapid Infusion
Jul. 2018	TREAKISYM® (bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018
Sep. 2019	SymBio Pharmaceuticals obtained from Chimerix (NASDAQ:CMRX) the exclusive worldwide rights to develop, manufacture, and commercialize brincidofovir (BCV) in all human indications, excluding the prevention and treatment of smallpox
Sep. 2020	SymBio Pharmaceuticals receives approval of TREAKISYM® Ready-To-Dilute (RTD) formulation
Dec. 2020	Commencement of in house sales of the anti cancer agent TREAKISYM®
Jan. 2021	Market Launch of TREAKISYM® Ready To Dilute (RTD) Formulation
Mar. 2021	SymBio Pharmaceuticals receives approval of TREAKISYM® (bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B cell lymphoma
Apr. 2021	SymBio Pharmaceuticals receives approval of TREAKISYM® Ready To Dilute (RTD) Formulation in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B cell lymphoma
Feb. 2022	SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM® Liquid Formulation

Organization Chart

As of September 11, 2023

